https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(MedPage Today) — A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical Hodgkin lymphoma (cHL), with outcomes similar to younger patients but with a significant toxicity cost…
